TriCelX seeks FDA green light for Alzheimer’s trial of XytriX

TriCelX has filed an FDA application to test its experimental cell-based biotherapeutic XytriX in people with mild Alzheimer’s disease and is also asking for Fast Track status. The move puts the company’s third brain-disease program into motion as Alzheimer’s becomes its largest and most ambitious target yet.

Why it matters: - Alzheimer’s affects about 7.4 million Americans age 65 and older, and care costs are projected to reach $409 billion this year. - The disease is also a global health burden, with 57 million people living with dementia worldwide in 2021 and about 10 million new cases each year. - TriCelX is now pursuing Alzheimer’s alongside CTE and ALS, putting three of its four FDA programs into brain diseases.

What happened: - TriCelX filed an application with the U.S. Food and Drug Administration on October 21, 2026, to test XytriX in people with mild Alzheimer’s disease. - The company is also requesting Fast Track designation. - The study is being designed for the mild stage of disease, not late-stage Alzheimer’s. - XytriX is an experimental biotherapeutic made from signaling cells found in donated umbilical cord tissue.

The details: - The planned study will enroll nine people with mild Alzheimer’s in three groups: vein, nose, or both. - The protocol may expand to as many as 18 participants. - Participants will receive three treatments, spaced four weeks apart, followed by two years of follow-up. - The study does not use a placebo, and every participant receives XytriX. - An FDA-cleared blood test, not a PET scan, will confirm diagnosis. - People taking blood thinners can participate. - The study’s first goal is safety. - Researchers will also track memory, daily function and brain inflammation on MRI. - The trial is running at the Baylor Scott & White Sports Therapy and Research Center in Frisco, Texas. - Board-certified neurosurgeon Dr. Abdul Baker is leading the study under an independent safety board. - The first person in the nasal group starts at half the dose, and the safety board reviews each step before the next participant is treated. - As of October 19, XytriX had only been given to people by injection into the knee. - TriCelX says this may be the first time the biotherapeutic is delivered into a vein or through the nose. - XytriX is produced at TriCelX’s cGMP, FDA-registered facility in Frisco. - The company says the same cell banks and standards are being used across its programs. - TriCelX has also asked the FDA to designate XytriX as an orphan drug for ALS, but that request has not been granted. - TriCelX expects to report initial results from the knee study’s first cohort before the end of 2026.

Between the lines: - TriCelX is betting on a network-level approach to brain disease rather than a single-target drug strategy. - Jakes Jordaan, the company’s founder, president and CEO, said most Alzheimer’s drug candidates have failed because they were aimed at one protein in a disease that affects the whole network. - Dr. Baker said the question is whether signaling cells can calm immune activity, support surviving neurons and help the brain regain balance. - The company is framing Alzheimer’s as a self-reinforcing loop of inflammation, vascular leakage and synaptic loss rather than one isolated defect. - TriCelX also points to prior work from another company’s adult bone-marrow cells in 49 people with mild Alzheimer’s, but does not claim those results for XytriX. - The company says the ALS program uses the same cells and delivery routes as the Alzheimer’s study, creating one development path across diseases.

What’s next: - FDA review will determine whether TriCelX can begin the Alzheimer’s study. - If cleared, the trial will test whether XytriX can be delivered safely by vein and nasal route in people with mild Alzheimer’s. - The broader program will continue to build on human safety data from the knee study while CTE, ALS and Alzheimer’s move through separate regulatory paths. - TriCelX says each disease will still need its own evidence that XytriX works.

The bottom line: - TriCelX is taking its riskiest step yet: moving a cell-based therapy from the knee into the brain-disease arena, where Alzheimer’s remains one of medicine’s hardest targets.